Vir Biotechnology, Inc. (VIR): EBITDA
-$467.65M
Year ended 2025-12-31
-$268.68M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$467.65M | n/m | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | -$572.61M | n/m | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | -$664.85M | n/m | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $839.85M | n/c | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $426.03M | n/m | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | -$292.58M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$174.69M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$117.07M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$81.24M | n/a | 2020-03-26, From 2017-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$467.65M | n/m |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | -$564.43M | n/m |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$262.25M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $237.0K | -96.2% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$93.43M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | -$154.85M | n/m |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$151.04M | n/m |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | -$240.50M | n/m |
| Agenus Inc (AGEN) | 2025-12-31 | -$10.17M | n/m |
Compare VIR, RXRX, AUTL, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗